Larynx preservation for patients with locally advanced laryngeal cancer

Journal of Clinical Oncology

Volumn 31, Issue 7, 2013, Pages 840-844

  Corry, June ^a   Peters, Lester ^a   Kleid, Stephen ^b   Rischin, Danny ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL;

ADULT; ADVANCED CANCER; ALCOHOL CONSUMPTION; ANESTHESIA; ARTICLE; CANCER RADIOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; GASTROINTESTINAL ENDOSCOPY; HEART RIGHT VENTRICLE; HOARSENESS; HUMAN; LARYNX CANCER; LARYNX CARTILAGE; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SMOKING; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; TUMOR BIOPSY; VOCAL CORD; VOCAL CORD DISORDER;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY, ADJUVANT; CISPLATIN; FLUOROURACIL; HOARSENESS; HUMANS; INDUCTION CHEMOTHERAPY; LARYNGEAL NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGAN SPARING TREATMENTS; SMOKING; SMOKING CESSATION; TAXOIDS; TREATMENT OUTCOME; VOCAL CORDS; XEROSTOMIA;

EID: 84875707973     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.46.9197     Document Type: Article

References (22)

1. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer: The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 324:1685-1690, 1991.
2. Forastiere AA, Goepfert H, Maor M, et al: Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349:2091-2098, 2003.
3. Pointreau Y, Garaud P, Chapet S, et al: Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 101:498-506, 2009.
4. Janssens GO, Rademakers SE, Terhaard CH: Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: Results of a phase III randomized trial. J Clin Oncol 30:1777-1783, 2012.
5. Forastiere AA, Zhang Q, Weber RS, et al: Long-term results of RTOG 91-11: A comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 31:845-852, 2013.
6. Lefebvre JL, Rolland F, Tesselaar M, et al: Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. J Natl Cancer Inst 101:142-152, 2009.
7. Posner MR, Hershock DM, Blajman CR, et al: Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357:1705- 1715, 2007.
8. Vermorken JB, Remenar E, van Herpen C, et al: Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357:1695- 1704, 2007.
9. Feng FY, Kim HM, Lyden TH, et al: Intensitymodulated radiotherapy of head and neck cancer aiming to reduce dysphagia: Early dose-effect relationships for the swallowing structures. Int J Radiat Oncol Biol Phys 68:1289-1298, 2007.
10. Frowen J, Cotton S, Corry J, et al: Impact of demographics, tumor characteristics, and treatment factors on swallowing after (chemo)radiotherapy for head and neck cancer. Head Neck 32:513-528, 2010.
11. Loevner LA, Sonners AI, Schulman BJ, et al: Reinterpretation of cross-sectional images in patients with head and neck cancer in the setting of a multidisciplinary cancer center. AJNR Am J Neuroradiol 23:1622-1626, 2002.
12. Connell CA, Corry J, Milner AD, et al: Clinical impact of, and prognostic stratification by, F-18 FDG PET/CT in head and neck mucosal squamous cell carcinoma. Head Neck 29:986-995, 2007.
13. Cohen EE, Karrison T, Kocherginsky M, et al: DeCIDE: A phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 30, 2012 (suppl; abstr 5500).
14. Haddad RI, Rabinowits G, Tishler RB, et al: The PARADIGM trial: A phase III study comparing sequentialtherapy (ST) to concurrent chemoradiotherapy (CRT) in locally advanced head and neck cancer (LANHC). J Clin Oncol 30, 2012 (suppl; abstr 5501).
15. Overgaard J, Hansen HS, Specht L, et al: Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 362:933-940, 2003.
16. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578, 2006.
17. Calais G, Alfonsi M, Bardet E, et al: Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advancedstage oropharynx carcinoma. J Natl Cancer Inst 91:2081-2086, 1999.
18. Gillison ML, Zhang Q, Jordan R: Tobacco smoking and increased risk of death and progression for p16-positive and p16-negative oropharyngeal cancer. J Clin Oncol 30:2102-2111, 2012.
19. Land SR: Methodologic barriers to addressing critical questions about tobacco and cancer prognosis. J Clin Oncol 30:2030-2032, 2012.
20. NCCN Guidelines: Head and neck cancers, 2012. http://www.nccn.org/ professionals/physician-gls/pdf/head-and-neck.pdf.
21. Corry J, Rischin D, Cotton S, et al: Larynx preservation with primary non-surgical treatment for loco-regionally advanced larynx cancer. J Med Imaging Radiat Oncol 55:229-235, 2011.
22. Peters LJ, O'Sullivan B, Giralt J, et al: Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: Results from TROG 02.02. J Clin Oncol 28:2996-3001, 2010.